Ketoconazole increases the plasma levels of ivermectin in sheep

Veterinary Parasitology

Volumn 157, Issue 1-2, 2008, Pages 117-122

  Alvinerie, Michel ^a   Dupuy, Jacques ^a   Kiki Mvouaka, Solange ^a   Sutra, Jean François ^a   Lespine, Anne ^a  

^a CEMAGREF   (France)

Author keywords

Drug drug interaction; Ketoconazole; Macrocyclic lactone; P glycoprotein; Resistance; Sheep

Indexed keywords

DRUG METABOLITE; GLYCOPROTEIN P; IVERMECTIN; KETOCONAZOLE; LACTONE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LAMB; MORNING DOSAGE; NONHUMAN; SHEEP; SINGLE DRUG DOSE;

ANIMALS; ANTHELMINTICS; ANTIFUNGAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; IVERMECTIN; KETOCONAZOLE; SHEEP;

ANIMALIA; OVIS ARIES;

EID: 51249101705     PISSN: 03044017     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetpar.2008.06.017     Document Type: Article

References (33)

1. Alvinerie M., Dupuy J., Eeckhoutte C., and Sutra J.F. Enhanced absorption of pour-on ivermectin formulation in rats by co-administration of the multidrug-resistant-reversing agent verapamil. Parasitol. Res. 85 (1999) 920-922
2. Alvinerie, M., Tardieu, D., Sutra, J., D, Bojensen, G., Galtier, P., 1994. Metabolic profile of ivermectin in goats: an "in vivo" and "in vitro" evaluation (ed.) 1994. EAVPT International Congress, Edinburgh, Scotland. August 7-11, 1994.
3. Ballent M., Lifschitz A., Virkel G., Sallovitz J., and Lanusse C. Modulation of the P-glycoprotein-mediated intestinal secretion of ivermectin: in vitro and in vivo assessments. Drug Metab. Dispos. 34 (2006) 457-463
4. Ballent M., Lifschitz A., Virkel G., Sallovitz J., and Lanusse C. Involvement of P-glycoprotein on ivermectin kinetic behaviour in sheep: itraconazole-mediated changes on gastrointestinal disposition. J. Vet. Pharmacol. Ther. 30 (2007) 242-248
5. Bourrie M., Meunier V., Berger Y., and Fabre G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol. Exp. Ther. 277 (1996) 321-332
6. Chiu S.H., Taub R., Sestokas E., Lu A.Y., and Jacob T.A. Comparative in vivo and in vitro metabolism of ivermectin in steers, sheep, swine, and rat. Drug Metab. Rev. 18 (1987) 289-302
7. Griffin J., Fletcher N., Clemence R., Blanchflower S., and Brayden D.J. Selamectin is a potent substrate and inhibitor of human and canine P-glycoprotein. J. Vet. Pharmacol. Ther. 28 (2005) 257-265
8. Grimm S.W., Richtand N.M., Winter H.R., Stams K.R., and Reele S.B. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br. J. Clin. Pharmacol. 61 (2006) 58-69
9. Hugnet C., Lespine A., and Alvinerie M. Multiple oral dosing of ketoconazole increases dog exposure to ivermectin. J. Pharm. Pharm. Sci. 10 (2007) 311-318
10. Kageyama M., Namiki H., Fukushima H., Ito Y., Shibata N., and Takada K. In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats. Biol. Pharm. Bull. 28 (2005) 316-322
11. Kaplan R.M. Drug resistance in nematodes of veterinary importance: a status report. Trends Parasitol. 20 (2004) 477-481
12. Kovarik J.M., Beyer D., Bizot M.N., Jiang Q., Shenouda M., and Schmouder R.L. Blood concentrations of everolimus are markedly increased by ketoconazole. J. Clin. Pharmacol. 45 (2005) 514-518
13. Kuroha M., Shirai Y., and Shimoda M. Multiple oral dosing of ketoconazole influences pharmacokinetics of quinidine after intravenous and oral administration in beagle dogs. J. Vet. Pharmacol. Ther. 27 (2004) 355-359
14. Kwei G.Y., Alvaro R.F., Chen Q., Jenkins H.J., Hop C.E., Keohane C.A., Ly V.T., Strauss J.R., Wang R.W., Wang Z., Pippert T.R., and Umbenhauer D.R. Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein. Drug Metab. Dispos. 27 (1999) 581-587
15. Laffont C.M., Toutain P.L., Alvinerie M., and Bousquet-Melou A. Intestinal secretion is a major route for parent ivermectin elimination in the rat. Drug Metab. Dispos. 30 (2002) 626-630
16. Lifschitz A., Virkel G., Sallovitz J., Sutra J.F., Galtier P., Alvinerie M., and Lanusse C. Comparative distribution of ivermectin and doramectin to parasite location tissues in cattle. Vet. Parasitol. 87 (2000) 327-338
17. Lifschitz A.L., Virkel G.L., Sallovitz J.M., Pis A., Imperiale F.A., and Lanusse C.E. Loperamide modifies the tissue disposition kinetics of ivermectin in rats. J. Pharm. Pharmacol. 56 (2004) 61-67
18. Maurice M., Pichard L., Daujat M., Fabre I., Joyeux H., Domergue J., and Maurel P. Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J. 6 (1992) 752-758
19. McKellar Q.A., and Benchaoui H.A. Avermectins and milbemycins. J. Vet. Pharmacol. Ther. 19 (1996) 331-351
20. Mealey K.L., Bentjen S.A., Gay J.M., and Cantor G.H. Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics 11 (2001) 727-733
21. Molento M.B., Lifschitz A., Sallovitz J., Lanusse C., and Prichard R. Influence of verapamil on the pharmacokinetics of the antiparasitic drugs ivermectin and moxidectin in sheep. Parasitol. Res. 92 (2004) 121-127
22. Molyneux D.H., Bradley M., Hoerauf A., Kyelem D., and Taylor M.J. Mass drug treatment for lymphatic filariasis and onchocerciasis. Trends Parasitol. 19 (2003) 516-522
23. Ogasawara, A., Kume, T., Kazama, E., 2007. Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys. Drug Metab. Dispos. 35, 410-418.
24. Perrier D., and Mayersohn M. Noncompartmental determination of the steady-state volume of distribution for any mode of administration. J. Pharm. Sci. 71 (1982) 372-373
25. Pouliot J.F., L'Heureux F., Liu Z., Prichard R.K., and Georges E. Reversal of P-glycoprotein-associated multidrug resistance by ivermectin. Biochem. Pharmacol. 53 (1997) 17-25
26. Prichard R.K., and Roulet A. ABC transporters and beta-tubulin in macrocyclic lactone resistance: prospects for marker development. Parasitology 134 (2007) 1123-1132
27. Ridtitid W., Wongnawa M., Mahatthanatrakul W., Raungsri N., and Sunbhanich M. Ketoconazole increases plasma concentrations of antimalarial mefloquine in healthy human volunteers. J. Clin. Pharm. Ther. 30 (2005) 285-290
28. Roulet A., Puel O., Gesta S., Lepage J.F., Drag M., Soll M., Alvinerie M., and Pineau T. MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. Eur. J. Pharmacol. 460 (2003) 85-91
29. Sangster N.C., Bannan S.C., Weiss A.S., Nulf S.C., Klein R.D., and Geary T.G. Haemonchus contortus: sequence heterogeneity of internucleotide binding domains from P-glycoproteins. Exp. Parasitol. 91 (1999) 250-257
30. Schinkel A.H., Smit J.J., van Tellingen O., Beijnen J.H., Wagenaar E., van Deemter L., Mol C.A., van der Valk M.A., Robanus-Maandag E.C., te Riele H.P., et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77 (1994) 491-502
31. Ward K.W., Stelman G.J., Morgan J.A., Zeigler K.S., Azzarano L.M., Kehler J.R., McSurdy-Freed J.E., Proksch J.W., and Smith B.R. Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey. Drug Metab. Dispos. 32 (2004) 172-177
32. Xu M., Molento M., Blackhall W., Ribeiro P., Beech R., and Prichard R. Ivermectin resistance in nematodes may be caused by alteration of P-glycoprotein homolog. Mol. Biochem. Parasitol. 91 (1998) 327-335
33. Yamakoa K., Tanigavara K., Nokaguana K., and Unot T. A pharmacokinetic analysis program (multi) for microcomputer. J. Pharmacobiol. Dyn. 4 (1981) 879-885